Replies to post #72211 on Biotech Values

[jbog]

Dew,

Do you recall any of the history or potential of the Dimebon program.

If I recall pfe paid medivation around $200 mil last year. Medivation is only up a couple of pennies today.

[masterlongevity]

Bapineuzimab..

i agree. Would not be surprised if they booted it back to Elan...
i think elan is in real trouble. tysabri is going to have some new stiff competition in 1 yr and bapineuzimab is still 3+ yrs from market, assuming it works.